Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GIANT BIOGENE HOLDING CO., LTD
巨子生物控股有限公司

(An exempted company incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 MAY 2026 AND PAYMENT OF FINAL DIVIDEND AND SPECIAL DIVIDEND

At the annual general meeting (the "**AGM**") of Giant Biogene Holding Co., Ltd (the "**Company**") held on 28 May 2026, all the proposed resolutions as set out in the notice of the AGM dated 6 May 2026 were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive the audited consolidated financial statements, directors' report and auditor's report of the Company for the year ended 31 December 2025.	670,207,132 (96.94%)	21,184,982 (3.06%)
2.	(a) To re-elect Ms. Fang Juan as an executive director;	682,039,861 (98.65%)	9,343,453 (1.35%)
	(b) To re-elect Ms. Zhang Huijuan as an executive director;	682,457,538 (98.71%)	8,925,776 (1.29%)
	(c) To re-elect Ms. Yan Yubo as an executive director; and	682,357,387 (98.69%)	9,025,927 (1.31%)
	(d) To authorize the board of directors to fix the respective directors' remuneration.	691,346,948 (99.99%)	36,366 (0.01%)
3.	To appoint KPMG as the independent auditor of the Company, following the retirement of Ernst & Young, to hold office until the conclusion of the next annual general meeting of the Company and authorise the Board of Directors to fix its remuneration.	691,383,314 (100%)	0 (0%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
4.	To grant a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the total issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution.	691,376,033 (99.99%)	7,281 (0.01%)
5.	To grant a general mandate to the directors of the Company to allot, issue and deal with additional shares not exceeding 20% of the total issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution.	633,216,821 (91.59%)	58,166,493 (8.41%)
6.	To extend, conditional upon the passing of resolutions no. 4 and 5 above, the general mandate granted to the directors of the Company pursuant to resolution no. 5 to issue shares by adding the number of shares repurchased under ordinary resolution no. 4 to the number of issued shares of the Company.	634,929,771 (91.83%)	56,453,543 (8.17%)
7.	(a) To declare and distribute a final dividend of RMB0.5390 per ordinary share for the year ended 31 December 2025 to the shareholders of the Company;	691,383,314 (100%)	0 (0%)
	(b) To declare and distribute a special dividend of RMB0.6714 per ordinary share for the year ended 31 December 2025 to the shareholders of the Company.	691,383,314 (100%)	0 (0%)

Notes:

(a) As over 50% of the votes were cast in favour of each of the resolutions numbered 1 to 7, resolutions 1 to 7 were duly passed as ordinary resolutions.

(b) As at the date of the AGM, the total number of shares of the Company in issue was 1,061,704,000 shares.

(c) The total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 1,061,704,000 shares. The Company did not hold any treasury shares (including any treasury shares held or deposited with Central Clearing and Settlement System) as at the date of the AGM.

(d) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules").

(e) No shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM.

(f) None of the shareholders of the Company have stated their intention in the Company's circular dated 6 May 2026 to vote against or to abstain from voting on any of the resolutions at the AGM.

(g) The Company's branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

(h) All directors of the Company attended (physically or online) the AGM.

PAYMENT OF THE FINAL DIVIDEND AND SPECIAL DIVIDEND

Following the approval by the Shareholders at the AGM, the Board is pleased to announce that the Company will distribute a final dividend of RMB0.5390 per ordinary share (equivalent to HK$0.6187) and special dividend of RMB0.6714 per ordinary share (equivalent to HK$0.7707) on or around Thursday, 25 June 2026 to the Shareholders whose names appear on the register of members of the Company on Monday, 8 June 2026. The relevant exchange rate will be the central parity rate of RMB to Hong Kong dollars as announced by the People's Bank of China on the date of the AGM (RMB0.87115 equivalent to HK$1.00) and the amount of final dividend and special dividend in Hong Kong dollar was rounded to 4 decimal places. For the purpose of ascertaining the Shareholders' entitlement to the final dividend and special dividend, the register of members of the Company will be closed from Wednesday, 3 June 2026 to Monday, 8 June 2026, both days inclusive, during which period no transfer of Shares will be registered. In order to be eligible to receive the final dividend and special dividend, all Share transfer documents, accompanied by the relevant share certificates, must be lodged with the Company's Share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration by 4:30 p.m. on Tuesday, 2 June 2026.

By order of the Board
Giant Biogene Holding Co., Ltd
Yan Jianya
Chairman of the Board

Xi'an, the PRC, 28 May 2026

As of the date of this announcement, the Board comprises Mr. Yan Jianya, Ms. Ye Juan, Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo as executive directors, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive directors.